6c3fd2dd__Trials_Monthly___October_2013__Description
[NCI Designation] NCT01647789 [Disease Site] Prostate Cancer [Description] 
A Phase I/II, Multicenter, Open-Label Dose Finding Study of Oral CFG920 in Patients with Metastatic Castration-Resistant Prostate Cancer
Seattle Cancer Care Alliance | Clinical Trials Monthly - October 2013
Description